Cochrane COVID-19 Studienregister
NCT05074420Erstmals veröffentlicht: 2021 Okt 12Letzte Aktualisierung: 2021 Okt 12

A Multicenter, Open-Label, Pharmacokinetic and Safety Study of Baricitinib in Pediatric Patients From 1 Year to Less Than 18 Years Old Hospitalized With COVID-19

  1. Studientyp
  2. Interventional
  1. Studienziel
  2. Treatment and Management
  1. Studiendesign
  2. Single Arm/Controlled Before After
  1. Interventionszuordnung
  2. Not Applicable

A Study of Baricitinib (LY3009104) in Children With COVID-19 (COV-BARRIER-PEDS)

Eintrag in Studienregister
Keine Ergebnisse
The purpose for this study is to determine if the study drug baricitinib is effective and safe in hospitalized pediatric participants with Coronavirus disease 2019 (COVID -19) and to confirm the dose